UPDATE: Qiagen to Buy Cellestis for $355M

The deal provides Qiagen with access to Cellestis' QuantiFeron "pre-molecular" testing technology for detecting and monitoring disease.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories